
## Khairuddin Memon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11217090/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 497-507.e2.	1.3	566
2	Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization. Clinical Gastroenterology and Hepatology, 2013, 11, 1358-1365.e1.	4.4	220
3	Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. Journal of Hepatology, 2013, 59, 1029-1036.	3.7	215
4	Research Reporting Standards for Radioembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology, 2011, 22, 265-278.	0.5	185
5	Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times. Gastroenterology, 2011, 141, 526-535.e2.	1.3	148
6	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic–pathologic correlation. Journal of Hepatology, 2011, 54, 695-704.	3.7	140
7	Radioembolization for Neuroendocrine Liver Metastases: Safety, Imaging, and Long-Term Outcomes. International Journal of Radiation Oncology Biology Physics, 2012, 83, 887-894.	0.8	137
8	Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. Journal of Hepatology, 2013, 58, 73-80.	3.7	110
9	Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. Journal of Hepatology, 2012, 56, 1112-1120.	3.7	82
10	Radioembolization for Primary and Metastatic Liver Cancer. Seminars in Radiation Oncology, 2011, 21, 294-302.	2.2	78
11	Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology, 2013, 58, 1655-1666.	7.3	66
12	Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: Analyzing patterns of progression in 285 patients. Hepatology, 2012, 55, 1432-1442.	7.3	64
13	Chemoembolization and Radioembolization for Metastatic Disease to the Liver: Available Data and Future Studies. Current Treatment Options in Oncology, 2012, 13, 403-415.	3.0	38
14	Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. European Journal of Radiology, 2017, 93, 100-106.	2.6	30
15	Yttrium 90 Microspheres for the Treatment of Hepatocellular Carcinoma. Recent Results in Cancer Research, 2013, 190, 207-224.	1.8	28
16	Cancer Concepts and Principles: Primer for the Interventional Oncologist—Part II. Journal of Vascular and Interventional Radiology, 2013, 24, 1167-1188.	0.5	26
17	Hepatic yttrium-90 radioembolization for metastatic melanoma. Melanoma Research, 2014, 24, 244-251.	1.2	23
18	Yttrium-90 Radioembolization for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology, 2013, 24, 74-80.	0.5	21

#	Article	IF	CITATIONS
19	Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 486-493.	6.4	21
20	Comparative Study of Staging Systems for Hepatocellular Carcinoma in 428 Patients Treated with Radioembolization. Journal of Vascular and Interventional Radiology, 2014, 25, 1056-1066.	0.5	20
21	Prospective Evaluation of Patients with Early-/Intermediate-stage Hepatocellular Carcinoma with Disease Progression Following Arterial Locoregional Therapy: Candidacy for Systemic Treatment or Clinical Trials. Journal of Vascular and Interventional Radiology, 2013, 24, 1189-1197.e2.	0.5	18
22	Perfusion Reduction at Transcatheter Intraarterial Perfusion MR Imaging: A Promising Intraprocedural Biomarker to Predict Transplant-Free Survival during Chemoembolization of Hepatocellular Carcinoma. Radiology, 2014, 272, 587-597.	7.3	17
23	Embolic Therapies. , 2013, , 101-113.		0
24	Chemoembolization and Radioembolization in the Treatment of Primary Liver Cancers. , 2013, , 327-338.		0